We Are Revolutionizing
AireHealth’s digital health solution fits easily into a healthcare provider's new or existing chronic respiratory management program to help clinicians remotely engage and monitor their high-risk COPD and asthma patients, close gaps in care, and reduce care costs.
We’d love to tell you more about AireHealth’s digital health solution for your high-risk respiratory patients.SCHEDULE A CALL
Positively Impact Your Patients' Care
As a healthcare provider, your patients come to you searching for solutions. As chronic respiratory disease progresses, some patients may find it increasingly difficult to use proper technique when using a metered dose inhaler or dry powder inhaler to administer their respiratory medications.
Clinical guidelines support prescribing nebulized medications based on patient preference, economic factors and physical abilities.
Improve Treatment Adherence
Prescribing nebulized respiratory medications for your severe COPD and asthma patients who have reduced muscle strength, poor hand-breath coordination, reduced peak inspiratory flow and prolonged exhalation may improve medication adherence. 1,2, 3
The AireHealth Difference
AireHealth's portable-connected nebulizer seamlessly integrates with an innovative diary companion app to provide patients and clinicians with measurable data and insights.
✔️ Helps to support proactive clinical intervention and prevent unnecessary hospitalization and ER visits.
✔️ Portable, silent and simple-to-use design fits easily into a patient’s pocket or purse. FDA cleared Class II and HIPAA compliant medical device. Meets TSA travel standards.
✔️ Delivers nebulized medications quickly and efficiently without the hassle of an air compressor or tubing.
Learn more about how AireHealth's respiratory care platform can enhance care for you and your patients.GET 1 PAGER
1. Dhand, R. and et al. The Role of Nebulized Therapy in the Management of COPD Evidence and Recommendations. COPD. 2012:9:58-72. 2. Wise RA, Acevedo RA, Anzueto AR, et al. Guiding principles for the use of nebulized long-acting beta2-agonists in patients with COPD: An expert panel consensus. Chronic Obstr Pulm Dis. 2017; 4(1): 7-20. doi: http://doi.org/10.15326/jcopdf.4.1.2016.0141 3. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD Report 2021)